AVANIR Pharmaceuticals Invites Investors to Rodman & Renshaw Techvest Healthcare Conference Webcast

SAN DIEGO--(BUSINESS WIRE)--May 10, 2004--AVANIR Pharmaceuticals, (AMEX:AVN) today announced that its presentation at the Rodman & Renshaw Techvest Healthcare Conference will be Webcast live through the company's Web site at http://www.avanir.com. President and Chief Executive Officer Dr. Gerald J. Yakatan will be presenting at 10:10 a.m., 2:10 a.m. Pacific Daylight Time, on May 13th from the conference in London.

The live Webcast will be accessible through AVANIR's corporate Web site. To access the Webcast, please log on to AVANIR's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software. An archived version of the presentation will be available for 90 days following the conference.

AVANIR Pharmaceuticals is a drug discovery and development company focused on novel treatments for chronic diseases. The company's most advanced product candidate, Neurodex(TM), is in Phase III clinical development for pseudobulbar affect, also known as emotional lability. Neurodex(TM) is in Phase II clinical development for neuropathic pain. A potential treatment for allergy and asthma, AVP-13358, is in Phase I clinical development. AVANIR also develops human monoclonal antibodies for infectious diseases and other therapeutic applications. The company's first commercialized product, Abreva(R), is marketed in North America by GlaxoSmithKline Consumer Healthcare and is the leading over-the-counter product for the treatment of cold sores. Further information about AVANIR can be found at www.avanir.com.

The information contained in this press release, including any forward-looking statements contained herein, should be reviewed in conjunction with the company's most recent Annual Report on Form 10-K and other publicly available information regarding the company. Copies of such information are available from the company upon request. Such publicly available information sets forth many risks and uncertainties related to the company's business and technology. Forward-looking statements often contain such words like "estimate," "anticipate," "believe," "plan" or "expect." The company disclaims any intent or obligation to update these forward-looking statements. Final review decisions made by the FDA and other regulatory agencies concerning clinical trial results are unpredictable and outside the influence and/or control of the company.

CONTACT: AVANIR Pharmaceuticals
Investor Relations:
Patrice Saxon, 858-622-5202
psaxon@avanir.com

SOURCE: AVANIR Pharmaceuticals